Alternate Delegate Position AVMA

Thank you, Dr Ylander

The NVMA board of directors, and membership, is grateful for the many years Dr. David Ylander has volunteered on the House of Delegates with the American Veterinary Medical Association. After serving since 2006, Dr. Ylander will be stepping down following the 2023 AVMA annual conference in July.

Dr. Ylander has been a dedicated volunteer of the NVMA for a large part of his career, serving on the board of directors since 2002. As AVMA delegate, he has represented veterinarians, students, and technicians with professionalism and integrity on the national level.

Thank you Dr. Ylander for all you have done and will continue to do for the veterinary profession in Nebraska. The time you have given to veterinary medicine has not gone unnoticed.

Are you interested in serving as AVMA Alternate Delegate?

The NVMA board of directors is seeking candidates for the position of AVMA Alternate Delegate.

What are the expectations of the AVMA Alternate Delegate?

- Study the issues of the AVMA House of Delegates and present to the NVMA board of directors for input.

- Represent Nebraska veterinarians, students, and technicians on issues pertinent to those practicing in Nebraska.

- Attend all AVMA House of Delegate meetings, which are currently held in January and July/August each year. The AVMA pays for travel expenses associated with the meeting.

- Attend all NVMA board of directors meetings as a voting member.

Criteria to be considered for the position:

- Must have been an active member of the NVMA for the past 5 years.

- Must be an active member of the AVMA.

- Must be able to commit to necessary travel.

- Should be able to understand and leverage power and politics in organizations.

- Should be a good communicator and work well with others.

- Preference given to candidates who have attended the AVMA Veterinary Leadership Conference.

Interested candidates should submit a letter of interest, a CV, and any letters of reference to the NVMA board of directors by June 15 for consideration. Materials may be emailed to: nvmaorg@gmail.com. Additional information may be found on the website at www.nvma.org/leadership/

Compounding: How do new rules affect you?

shared with permission from the American Veterinary Medical Association

The U.S. Food and Drug Administration has announced that in April it will begin phasing in inspectional activities in relation to Guidance for Industry #256, Compounding Animal Drugs from Bulk Drug Substances.

In this guidance, the FDA specifies the circumstances in which it plans to exercise enforcement discretion for relevant violations of the federal Food, Drug, and Cosmetic Act for drug approval, labeling, and manufacturing. This means that although compounding from bulk substances for animal patients is still considered illegal, pharmacists and veterinarians may compound drugs in this way, without concern for enforcement action, provided they follow the guidance and adhere to certain criteria.

When it comes to enforcement, the FDA indicates it has no plans to inspect veterinary care facilities that do not compound animal drugs from bulk drug substances. Rather, it anticipates a limited number of inspections of state-licensed pharmacies. With regard to those inspections, the FDA indicates it will “afford individuals and firms an opportunity to voluntarily take appropriate and corrective action prior to the initiation of enforcement action.”

The FDA also does not intend to conduct routine inspections of federally registered outsourcing facilities that compound drugs until it provides clarification on how GFI #256 applies to them.

What you need to know

To understand how GFI #256 may impact your own prescribing and dispensing practices, check out the extensive resources at avma.org/GFI256. These include details of how the guidance affects veterinarians, FAQs, a new one-page summary of key points, and a free webinar led by FDA veterinarian Dr. Amber McCoig.

You’ll also find information about how the AVMA advocated on behalf of veterinarians throughout the FDA’s process of developing this guidance. AVMA made clear to the regulators the nuances and importance of veterinary access to compounding, including from bulk drug substances.

Championing veterinary needs

The AVMA actively works with the FDA to ensure that veterinarians have medically appropriate access to compounded drugs, including those prepared from bulk drug substances, and that veterinary access is not unduly burdensome. The Association will continue to advocate for changes if implementation of the guidance does not meet veterinarians’ needs.